Disparities in OUD treatment: Buprenorphine vs. naltrexone

Researchers from Icahn School of Medicine at Mount Sinai analyzed over 176,000 opioid-related healthcare events from January 2017 to December 2022 using HealthVerity Marketplace's Private Source 20 database (covering ~70M commercial, 60M Medicaid, and 15M Medicare Advantage enrollees) to see whether patients received buprenorphine or naltrexone within 180 days of an opioid-related event. White patients had a 20.5% adjusted probability of receiving buprenorphine versus 17.1% for Black and 16.2% for Hispanic patients, though no significant racial/ethnic differences appeared for naltrexone; by insurance type, 20.5% of Medicaid patients received buprenorphine versus 12.5% for Medicare Advantage and 13.1% for commercial, and Medicaid/Medicare Advantage patients had lower odds of receiving naltrexone than commercially insured patients.

HealthVerity is a real-world-data marketplace aggregating claims, EHR and lab data from 75+ sources via a proprietary patient-matching layer.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.